Compare RLJ & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | MLTX |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | United States | Switzerland |
| Employees | 73 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | RLJ | MLTX |
|---|---|---|
| Price | $8.18 | $18.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $7.83 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.17 | N/A |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | $188.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.54 | $5.95 |
| 52 Week High | $8.63 | $62.75 |
| Indicator | RLJ | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 56.71 |
| Support Level | $7.28 | $15.37 |
| Resistance Level | $8.59 | $19.02 |
| Average True Range (ATR) | 0.24 | 1.28 |
| MACD | 0.09 | 0.15 |
| Stochastic Oscillator | 98.10 | 77.78 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.